Table 1 Baseline characteristics

From: Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study

Characteristics

Arm A (n = 30)

Arm B (n = 21)

Age (years), median (range)

65 (19–74)

67 (53–73)

Sex, n (%)

 Male

28 (93.3)

17 (81.0)

 Female

2 (6.7)

4 (19.0)

ECOG performance status, n (%)

 0

23 (76.7)

10 (47.6)

 1

7 (23.3)

11 (52.4)

Smoking, n (%)

 Non-smoker

5 (16.7)

6 (28.6)

 Former/current smoker

25 (83.3)

15 (71.4)

Clinical stage, n (%)

 IIB

1 (3.3)

1 (4.8)

 IIIA

26 (86.7)

18 (85.7)

 IIIB

3 (10.0)

2 (9.5)

Clinical nodal status, n (%)

 N0

9 (30.0)

4 (19.0)

 N1

7 (23.3)

5 (23.8)

 N2

14 (46.7)

12 (57.1)

Histological type, n (%)

 Squamous cell carcinoma

20 (66.7)

16 (76.2)

 Non-squamous cell carcinoma

10 (33.3)

5 (23.8)

PD-L1 expression, n (%)

 <1%

12 (40.0)

0 (0)

 1%–49%

7 (23.3)

12 (57.1)

 ≥50%

0 (0)

9 (42.9)

 Unknown

11 (36.7)

0 (0)

Back to article page